Nitrogen Of The Hetero Ring Is Shared By An Additional Cyclo Of The Polycyclo Ring System Patents (Class 540/579)
  • Patent number: 11396511
    Abstract: The present invention relates to compounds of [Formula A]: including N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide, 2-((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)carbamoyl)phenyl acetate, methods for preparing the compounds, and compositions including the compounds as active ingredients. The compounds of the present invention are very effective in anti-inflammation and pain relief. The compositions of the present invention are effective in preventing or treating inflammation and/or pain.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: July 26, 2022
    Assignee: FRONTBIO CO., LTD.
    Inventors: Hong Won Suh, Jae Yong Lee, Soon Sung Lim, Jeong Tae Lee, Seung Hwan Hwang, Sang Pil Jang, Sung Hwan Park, Jeong Ho Jeon, Hyun Min Lim, Ju Mi Lee
  • Patent number: 10968228
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine monomer compounds of formula (I) below and their synthetic precursors:
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: April 6, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
  • Patent number: 9822117
    Abstract: The present invention discloses pyridoindolobenz[b,d]azepines compositions of Formula 1, wherein Y is a single bond or a double bond. A and B are independently —(CH2)n—; and ‘n’ varies from 0 to 3. R1 to R10 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.
    Type: Grant
    Filed: March 2, 2014
    Date of Patent: November 21, 2017
    Assignee: DAYA DRUG DISCOVERIES, INC.
    Inventor: Parthasarathi Rajagopalan
  • Patent number: 9682984
    Abstract: The invention relates to new and improved processes for the preparation of Alcaftadine and pharmaceutically acceptable salts thereof as well as an intermediate for the preparation of Alcaftadine. The new process saves a number of steps compared to the known process and results in a higher yield.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: June 20, 2017
    Assignee: Crystal Pharma S.A.U.
    Inventors: Antonio Lorente Bonde-Larsen, Jesús Miguel Iglesias Retuerto, Franciso Javiér Gallo Nieto, Juan José Ferreiro Gil
  • Patent number: 9617274
    Abstract: Synthetic noribogaine preferably free of ibogaine and, optionally, one or more of other naturally occurring Tabernanth iboga alkaloids, is provided.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 11, 2017
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Richard D. Gless, Jr.
  • Patent number: 9580436
    Abstract: The present invention relates to an improved process of preparing substantially pure alcaftadine comprising reacting substantially pure compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to obtain alcaftadine:
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: February 28, 2017
    Assignee: ENALTEC LABS PRIVATE LIMITED
    Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
  • Patent number: 9469649
    Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: October 18, 2016
    Assignee: DEMERX, INC.
    Inventor: Robert M. Moriarty
  • Patent number: 9403817
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 2, 2016
    Assignee: DEMERX, INC.
    Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, Jr.
  • Patent number: 9403837
    Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 2, 2016
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Patent number: 9255105
    Abstract: The present invention is related to a substantially pure compound of structural formula (VIII), a process for the purification of a compound of structural formula (VIII) and an improved process of preparing an alcaftadine compound of structural formula (I).
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 9, 2016
    Assignee: ENALTEC LABS PRIVATE LIMITED
    Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
  • Patent number: 9150584
    Abstract: Provided herein are indole and benzofuran fused isoquinuclidene derivatives. Also provided herein are processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (?) and (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: October 6, 2015
    Assignee: DEMERX, INC.
    Inventor: Robert M. Moriarty
  • Patent number: 9040520
    Abstract: Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 26, 2015
    Assignee: DemeRx, Inc.
    Inventors: Richard D. Gless, Jr., William C. Schinzer
  • Patent number: 9040519
    Abstract: This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: May 26, 2015
    Assignee: Medivation Technologies, Inc.
    Inventors: Sarvajit Chakravarty, Barry Patrick Hart, Rajendra Parasmal Jain
  • Publication number: 20150140489
    Abstract: Disclosed and claimed herein is a composition of matter having a general structure chosen from (I), (II), (III) or (IV); wherein X and Y are the same or different, wherein at least one of X and Y comprises an acid labile group, wherein R1 is a saturated or unsaturated group having from 1-4 carbon atoms, R2 is chosen from hydrogen or a saturated or unsaturated group having from 1-4 carbon atoms, R3 is a saturated or unsaturated group having from 1-4 carbon atoms, and R4 is a saturated or unsaturated group having from 1-4 carbon atoms.
    Type: Application
    Filed: October 21, 2014
    Publication date: May 21, 2015
    Inventors: Alex Philip Graham Robinson, Dongxu Yang, Andreas Frommhold, Thomas Lada, John L. Roth, Xiang Xue
  • Publication number: 20150133655
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 14, 2015
    Applicant: DEMERX, INC.
    Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, JR.
  • Publication number: 20150119570
    Abstract: The present invention is related to pure compound of structural formula (VIII), process for the purification of compound of structural formula (VIII) and improved process of preparing alcaftadine compound of structural formula (I).
    Type: Application
    Filed: November 19, 2013
    Publication date: April 30, 2015
    Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
  • Publication number: 20150094466
    Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 2, 2015
    Applicant: DemeRx, Inc.
    Inventor: Robert M. Moriarty
  • Publication number: 20150087633
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald D. Payan, Sylvia Braselmann
  • Patent number: 8946206
    Abstract: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Craig C. Garner, H. Craig Heller, Damien Colas, Daniel Z. Wetmore
  • Patent number: 8940728
    Abstract: This invention relates noribogaine derivatives, compositions and methods of use thereof.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: January 27, 2015
    Assignee: DemeRx, Inc.
    Inventors: Deborah C. Mash, Richard D. Gless, Jr., Robert M. Moriarty
  • Patent number: 8937061
    Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: January 20, 2015
    Assignee: DemeRx, Inc.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Publication number: 20150005492
    Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: DEMERX, INC.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Publication number: 20140357741
    Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Inventors: Deborah C. Mash, Richard D. Gless, JR.
  • Publication number: 20140357621
    Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
  • Publication number: 20140349992
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: November 27, 2014
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Patent number: 8877921
    Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: November 4, 2014
    Assignee: DemeRx, Inc.
    Inventor: Robert M. Moriarty
  • Publication number: 20140315837
    Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Inventors: Deborah C. Mash, Richard D. Gless
  • Publication number: 20140315891
    Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.
    Type: Application
    Filed: April 21, 2014
    Publication date: October 23, 2014
    Inventor: Deborah C. Mash
  • Patent number: 8859764
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: October 14, 2014
    Assignee: DemeRx, Inc.
    Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, Jr.
  • Publication number: 20140303144
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 9, 2014
    Applicant: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty
  • Patent number: 8853201
    Abstract: Disclosed herein are sulfate esters of noribogaine or 9,17 dihydronoribogaine, and pharmaceutically acceptable salts of each thereof, pharmaceutical compositions comprising such compounds, and methods of their use, including in treating addiction and/or pain.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: October 7, 2014
    Assignee: DemeRx, Inc.
    Inventors: Richard D. Gless, Jr., Robert M. Moriarty
  • Publication number: 20140296209
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 2, 2014
    Applicant: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty
  • Publication number: 20140294805
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: September 2, 2011
    Publication date: October 2, 2014
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Patent number: 8846659
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 30, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, Michael A. Walker
  • Publication number: 20140255386
    Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
    Type: Application
    Filed: July 24, 2012
    Publication date: September 11, 2014
    Applicants: NORTH CAROLINA STATE UNIVERSITY, THE WISTAR INSTITUTE
    Inventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
  • Patent number: 8802832
    Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: August 12, 2014
    Assignee: DemeRx, Inc.
    Inventors: Deborah C. Mash, Richard D. Gless, Jr.
  • Patent number: 8796260
    Abstract: Compounds of Formula I: I (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: August 5, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Howard G. Selnick, Ian M. Bell
  • Publication number: 20140200209
    Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicants: ViiV Healthcare Company, Shionogi & Co., Ltd.
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Patent number: 8772301
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: July 8, 2014
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
  • Publication number: 20140187655
    Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.
    Type: Application
    Filed: May 10, 2011
    Publication date: July 3, 2014
    Inventors: Deborah C. Mash, Richard D. Gless, JR.
  • Patent number: 8765737
    Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: July 1, 2014
    Assignee: DemeRx, Inc.
    Inventors: Deborah C. Mash, Richard D. Gless, Jr.
  • Publication number: 20140179682
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 26, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Patent number: 8742096
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 3, 2014
    Assignee: DemeRx, Inc.
    Inventors: Robert M. Moriarty, Simon Mbua Ngale Efange
  • Patent number: 8741891
    Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: June 3, 2014
    Assignee: DemeRx, Inc.
    Inventor: Deborah C. Mash
  • Publication number: 20140120013
    Abstract: One aspect of the present invention relates to salts that are room-temperature ionic liquids (RTILs), methods of making them, and methods of using them in connection with temporary or permanent gas sequestration. Another aspect of the present invention relates to a class of solvents which can be transformed into RTILs by exposure to a gas, and methods of using them in connection with temporary or permanent gas sequestration.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 1, 2014
    Applicant: Georgetown University
    Inventors: Tao Yu, Richard G. Weiss, Taisuke Yamada, Mathew George
  • Publication number: 20140113878
    Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
    Type: Application
    Filed: August 4, 2011
    Publication date: April 24, 2014
    Inventors: Deborah C. Mash, Richard D. Gless, JR.
  • Patent number: 8703103
    Abstract: Sterically hindered imidazole ligands are described, along with their synthesis, which are capable of coordinating to Group 2 metals, such as: calcium, magnesium, strontium, in an eta-5 coordination mode which permits the formation of monomeric or dimeric volatile complexes. A compound comprising one or more polysubstituted imidazolate anions coordinated to a metal selected from the group consisting of barium, strontium, magnesium, radium or calcium or mixtures thereof. Alternatively, one anion can be substituted with and a second non-imidazolate anion. Synthesis of the novel compounds and their use to form BST films is also contemplated.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: April 22, 2014
    Assignee: Air Products and Chemicals, Inc.
    Inventors: John Anthony Thomas Norman, Melanie K. Perez, Moo-Sung Kim
  • Publication number: 20140107102
    Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 17, 2014
    Applicant: Allergan, Inc.
    Inventors: Jagdish Parasrampuria, Avner Ingerman, Frans Janssens, Anton Megens
  • Publication number: 20140088085
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
    Type: Application
    Filed: January 12, 2012
    Publication date: March 27, 2014
    Applicants: ARRAY BIOPHARMA, INC, VENTIRX PHARMACEUTICALS, INC
    Inventors: Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones, James Jeffry Howbert, Robert Hershberg, Joseph P. Lyssikatos, Hong Woon Yang
  • Publication number: 20140039182
    Abstract: The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 6, 2014
    Inventors: David A. Colby, Mark V. Riofski, Changho Han